Provided by Tiger Trade Technology Pte. Ltd.

3D MEDICINES

3.005
-0.415-12.13%
Volume:974.00K
Turnover:2.92M
Market Cap:775.29M
PE:-3.58
High:3.415
Open:3.415
Low:2.910
Close:3.420
52wk High:10.020
52wk Low:1.820
Shares:258.00M
HK Float Shares:258.00M
Volume Ratio:1.03
T/O Rate:0.38%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.840
ROE:-29.62%
ROA:-11.98%
PB:1.11
PE(LYR):-3.58
PS:1.87

Loading ...

Sellas Life Sciences Group Inc: 3D Medicines Will Continue Development & Commercialization of Galinpepimut-S in Greater China Territory

THOMSON REUTERS
·
Jul 28

Sellas Arbitration Claim Against 3D Medicines Dismissed, Owes $1 Million in Legal Fees

Reuters
·
Jul 28

3D Medicines Wins Hong Kong Arbitration; SELLAS Ordered to Pay HK$7.98 Million in Costs

Bulletin Express
·
Jul 27

Arbitration Panel Fully Rejects SELLAS Claims in Dispute With 3D MEDICINES

Stock News
·
Jul 27

3D Medicines Updates on Arbitration Proceedings Against Sellas Life Sciences

Reuters
·
Jul 27

3D Medicines - Sellas Ordered to Pay 3D Medicines HK$8 Mln in Arbitration Costs by Aug 7, 2026

THOMSON REUTERS
·
Jul 27

3D Medicines Inc - Arbitration Proceedings Against Sellas Life Sciences- Group

THOMSON REUTERS
·
Jul 27

3D Medicines - Sole Arbitrator Dismisses All Claims by Sellas Against 3D Medicines

THOMSON REUTERS
·
Jul 27

3D Medicines Reports Stable Share Capital for June 2026; 258.18 Million Shares in Issue, Public Float Maintained

Bulletin Express
·
Jul 07

3D Medicines: Xia Fang Confirmed as Qualified Company Secretary; Li Ching Yi to Step Down in June 2026

Bulletin Express
·
Jun 30

3D MEDICINES Appoints Xia Fang as Authorized Representative

Stock News
·
Jun 30

3D Medicines Names Xia Fang as Sole Company Secretary After Li Ching Yi Resignation

Reuters
·
Jun 30

3D Medicines Sets 30 June 2026 for AGM; Board Re-election, 20% Issuance Mandate and 10% Buy-back Limit on Agenda

Bulletin Express
·
Jun 05

3D Medicines sets 30 June 2026 AGM to seek 20% share-issue mandate, 10% buy-back limit and board re-elections

Bulletin Express
·
Jun 05

3D Medicines: Phase III Data on Envafolimab + GEMOX in First-Line Biliary Tract Cancer Secures ASCO 2026 Spotlight

Bulletin Express
·
May 27

3D Medicines says Phase III data for Envafolimab plus GEMOX in advanced biliary tract cancer to be presented at 2026 ASCO meeting

Reuters
·
May 27

3D MEDICINES (01244): Phase III Trial for ENVISTAR® in NSCLC Neoadjuvant/Adjuvant Setting Completes Enrollment Ahead of Schedule

Stock News
·
May 21

3D Medicines Completes Patient Enrollment Early in Phase III Envafolimab Trial for Resectable Stage III NSCLC

Bulletin Express
·
May 21

3D Medicines Reports No Change in Share Capital or Share Count for April 2026

Bulletin Express
·
May 06

3D MEDICINES 2025年业绩:核心产品年销达3.561亿元,研发投入持续加码

Bulletin Express
·
Apr 30